



**Dissecting immune responses following
controlled human schistosome infections
to guide vaccine design**

Dosage groups




Marijke Langenberg

Dermatitis




Adverse events


10 cercs



20 cercs




30 cercs




Number of weeks after exposure

AE increase with dose and peak at week 4-6

Eosinophils



CAA levels compared to endemic area



Conclusion

- First controlled human schistosome infection, model for testing novel products
- Safe at 20 cercs (but dose dependent tolerability)
- Katayama syndrome is not related to egg deposition
- Serum CAA at week 4-6 post exposure
- 40 mg/kg PZQ is insufficient to achieve 100% cure
- IgM seroconversion at 4-5 weeks
- IgG later at 12 weeks, primarily IgG1, no IgG4
- Antigen specific responses and cellular responses will follow

Parasitology:

Maria Yazdanbakhsh
Lisette van Lieshout
Ron Hokke
Jacqueline Janse
Marijke Langenberg
Carola Feijt
Munisha Ganesh
Marie-Astrid Hoogerwerf
Jan-Pieter Koopman
Janneke Kos
Arifa Ozir
Angela van Diepen
Eric Brienen
Govert van Dam
Pytsje Hoekstra
Yvonne Kruise
Beatrice Winkel
Roos van Schuijlenburg
Mikhael Manurung
Abena Amoah
Miriam Casacuberta
Erliyani Sartono

The volunteers

Infectious diseases:

Leo Visser
Kitty Suijk
Gerdien Hardeman
Jos Fehrmann
Petra Verbeek-Menken
Martijn Bauer

Cell and chemical biology:

Paul Corstjens
Claudia de Dood

Animal facility:

Jan-Bas Prins
Ewout Speksnijder

IGFL:

Pauline Meij
Maarten Zandvliet
Anton Terwisscha
Inge Westra


Medical Microbiology:

Martha van Beek
Marianne Erkens
Pauline vd Plas
Els Wessels
Yvette van Aarle
Jutte de Vries
Christel van Zeijl

Gijsbert van Willigen

IMI lab:

Fijs van Leeuwen
Clarize Korne
Danny van Willigen
Mick Welling
Matthias van Oosterom



L-CHiC

Beatrice Winkel TUES 30th, 8:15am session 58



L-CHiC

www.controlledhumaninfection.org